Barclays Increases Elevance Health (NYSE:ELV) Price Target to $512.00

Elevance Health (NYSE:ELV) had its target price upped by stock analysts at Barclays from $501.00 to $512.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 27.54% from the company’s previous close.

A number of other analysts have also weighed in on ELV. Argus lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Friday, October 18th. Truist Financial reduced their price objective on Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. TD Cowen dropped their target price on Elevance Health from $589.00 to $484.00 and set a “buy” rating for the company in a research report on Monday, October 21st. Cantor Fitzgerald reduced their price target on Elevance Health from $600.00 to $485.00 and set an “overweight” rating on the stock in a report on Friday, October 18th. Finally, StockNews.com upgraded shares of Elevance Health from a “hold” rating to a “buy” rating in a report on Friday, January 17th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $525.60.

Elevance Health Trading Up 0.0 %

Shares of ELV stock opened at $401.43 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.50 and a current ratio of 1.50. Elevance Health has a fifty-two week low of $362.21 and a fifty-two week high of $567.26. The company has a market cap of $93.10 billion, a PE ratio of 14.63, a P/E/G ratio of 1.11 and a beta of 0.84. The stock’s fifty day moving average price is $386.21 and its two-hundred day moving average price is $462.34.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 19.56% and a net margin of 3.68%. Equities analysts predict that Elevance Health will post 32.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Elevance Health

A number of hedge funds have recently added to or reduced their stakes in ELV. Raelipskie Partnership acquired a new stake in shares of Elevance Health during the 3rd quarter worth approximately $26,000. PSI Advisors LLC acquired a new stake in Elevance Health in the third quarter worth $27,000. Eastern Bank bought a new stake in Elevance Health in the third quarter valued at $31,000. Dunhill Financial LLC raised its holdings in shares of Elevance Health by 57.8% during the third quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock valued at $37,000 after purchasing an additional 26 shares during the period. Finally, Peterson Financial Group Inc. bought a new position in shares of Elevance Health during the 3rd quarter worth about $44,000. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.